$IMDX News

Last published 1w ago

1w agoIMDXiMDx to Release Third Quarter Results on November 16, 2026GlobeNewswireNASHVILLE, Tenn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report third quarter 2026 financial results after the market closes on
1mo agoIMDXiMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx LaunchGlobeNewswireNASHVILLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced the appointment of Donnie Purto as Senior Vice President of Sales to lead the company’s
1mo agoIMDXiMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor MeetingsGlobeNewswireNASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that on October 14, 2026, it will participate in the U.S. Bancorp I BTIG Kidney Health
2mo agoIMDXiMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” ConferenceGlobeNewswireNASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth
3mo agoIMDX BIOIMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDxGlobeNewswireDiscussions with FDA advance toward expected marketing authorization for GraftAssureDxFDA completes current portion of substantive review in a timely mannerFavorable Medicare reimbursement policy issued in July
3mo agoIMDXiMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 ConferenceGlobeNewswireNASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market closes on
3mo agoIMDXiMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group PublicationGlobeNewswireStudy published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejectionSerial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA)
4mo agoIMDXFavorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay PortfolioGlobeNewswireIndustry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testingSupports iMDx's commercial strategy in transplant monitoringFinal policy establishes recurring testing baseline
4mo agoIMDXIMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research PaperGlobeNewswireKey member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58Recent studies advanced science of molecular diagnostic
4mo agoIMDXiMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research GrantGlobeNewswire-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation- NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc.,
5mo agoIMDXFavorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical ChemistryGlobeNewswirePeer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitorGraftAssure's industry-leading reference change value (time-point to time-point
5mo agoIMDXIMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of TransplantationGlobeNewswireAmerican Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA aloneGraftAssure™ assay doubles reliability of positive
5mo agoIMDXiMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant CongressGlobeNewswireMultiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specificallyMajor transplantation conference in Boston will create
6mo agoIMDXIMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure CommercializationGlobeNewswireProgressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagementNortheast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial
6mo agoIMDXiMDx to Release First Quarter 2026 Results on May 13, 2026GlobeNewswireNASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on
7mo agoIMDX25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCEINSIGHT MOLECULAR DIAGNOSTICS INCEarnings Call TranscriptsGood morning. Thanks for joining us again at the 25th Annual Needham Healthcare Conference. I'm Mike Madsen, and I lead the MedTech and Diagnostics Equity Research Team at Needham and Company. I'm pleased to introduce In
7mo agoIMDXReal-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure AssayGlobeNewswirePositive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, ScotlandThree posters to be
7mo agoIMDXIMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 ResultsGlobeNewswireSubmitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second favorable head-to-head data set from an independent study at large hospital comparing
8mo agoIMDXSecond Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model ScoreGlobeNewswireNew data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary "Combination Model" score outperformed percentage-only measures of dd-cfDNAReinforces data
8mo agoIMDXInsight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA SubmissionGlobeNewswireThree-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White HealthSufficient clinical samples collected to support statistical analysis and FDA submissionCompany
9mo agoIMDXiMDx Announces $26.0 Million Registered Direct OfferingGlobeNewswireNASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), ("iMDx" or the "Company"), today announced that it has entered into definitive agreements with certain
10mo agoIMDXIMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant MonitoringGlobeNewswireAmerican Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key feature of iMDx's flagship GraftAssureTM family of assays NASHVILLE, Tenn.,
10mo agoIMDXiMDx Announces "JPM Week" and "BTIG Snowbird" Conference ParticipationGlobeNewswireNASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (NASDAQ:IMDX), today announced members of its management team will participate in the following investor conferences this
10mo agoIMDXiMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears CompletionGlobeNewswireGraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx™ FDA IVD approval application 95% complete at
1y agoIMDXIMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial LaunchGlobeNewswireOn track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025GraftAssure assay's head-to-head data
1y agoIMDXiMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following WeekGlobeNewswireNASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday,
1y agoIMDXiMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay LaunchGlobeNewswireSteven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future productsBrings 25 years of experience driving new product adoption across geographies in transplantation, oncology and
1y agoIMDXiMDx Reports Kidney Transplant Patient Achieved 'Immune Reset' with Novel Therapy and GraftAssure MonitoringGlobeNewswireAmerican Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to help avoid
1y agoIMDXInsight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and OrlandoGlobeNewswireIMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meetingPresenting on GraftAssureIQ
1y agoIMDXInsight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry DatabaseGlobeNewswire5,000-participant, multi-center registry supported by iMDx's central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for transplanted
1y agoIMDXIMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital ParticipantsGlobeNewswireiMDx's ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept.
1y agoIMDXiMDx to Participate in NYC Investment Conferences September 8 - 11GlobeNewswireNASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (NASDAQ:IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street
1y agoIMDXIMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular DiagnosticsGlobeNewswireBOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Empowered Patient Podcast with Karen Jagoda recently featured Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) (NASDAQ:IMDX), in an
1y agoIMDXIMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx LaunchGlobeNewswireReiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second
1y agoIMDXiMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics ConferenceGlobeNewswireNASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (NASDAQ:IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday,
1y agoIMDXIMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant PatientsGlobeNewswireiMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined scoreData show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens
1y agoIMDXiMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025GlobeNewswireNASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (NASDAQ:IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00
1y agoIMDXiMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection TestingGlobeNewswireStudy indicates iMDx flagship technology's equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx's digital PCR-based test kits with NGS kits shows consistent results in 96 transplant
1y agoOCX IMDXOncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to NashvilleGlobeNewswireNew name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at